Urinary Endothelin-1 As a Marker of Renal Damage in Sickle Cell Disease
Overview
Nephrology
Authors
Affiliations
Background: Sickle cell disease (SCD) affects the kidney by acute mechanisms as well as by insidious renal medullary/papillary necrosis, resulting in tubular defects, which increase the risk of dehydration and subsequent sickle crisis. Hypoxia has been reported to stimulate endothelin-1 (ET-1) synthesis by endothelial cells and also in the renal tubule.
Methods: This case-control study measured ET-1 in urine as a marker of its renal synthesis in asymptomatic SCD patients. Baseline plasma and urinary ET-1 levels were measured and followed during a water deprivation study and a subsequent administration of desmopressin.
Results: Urine and plasma levels of ET-1 were elevated in patients with SCD, compared with carefully matched African-French and African controls, and urine ET-1 excretion was associated with a marked urine-concentrating defect. Moreover, urinary ET-1 output was correlated with microalbuminuria in SCD patients.
Conclusions: ET-1 is known to antagonize the tubular effects of vasopressin and to promote renal scarring; increased renal production of ET-1 could produce nephrogenic diabetes insipidus and dehydration in SCD patients through a combination of fibrosis and functional resistance to vasopressin. This study provides a rationale for trials with endothelin receptor antagonists in sickle cell disease nephropathy.
End Organ Affection in Sickle Cell Disease.
Bathla T, Lotfollahzadeh S, Quisel M, Mehta M, Malikova M, Chitalia V Cells. 2024; 13(11.
PMID: 38891066 PMC: 11174153. DOI: 10.3390/cells13110934.
Sickle Cell Disease and CKD: An Update.
Zahr R, Saraf S Am J Nephrol. 2023; 55(1):56-71.
PMID: 37899028 PMC: 10872505. DOI: 10.1159/000534865.
Saurage E, Davis P, Meek R, Pollock D, Kasztan M Can J Physiol Pharmacol. 2022; 100(7):637-650.
PMID: 35413222 PMC: 10164438. DOI: 10.1139/cjpp-2022-0038.
The nephropathy of sickle cell trait and sickle cell disease.
Ataga K, Saraf S, Derebail V Nat Rev Nephrol. 2022; 18(6):361-377.
PMID: 35190716 PMC: 9832386. DOI: 10.1038/s41581-022-00540-9.
Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension.
Al-Qadi M, LeVarge B, Ford H Front Med (Lausanne). 2021; 7:616720.
PMID: 33842491 PMC: 8026868. DOI: 10.3389/fmed.2020.616720.